Nasdaq:BTMD
biote Corp.
Biote Corp. is a Nasdaq-listed biotechnology firm leveraging proprietary biological therapies to generate sustainable revenue growth in specialized medical markets.
Key Metrics
Investment Thesis
Bull Case
Biote Corp. presents a compelling value opportunity for contrarian investors given its substantial cash position of $39.3M against a relatively modest current liability base of $51.5M, offering potential for strategic acquisitions or debt reduction. The consistent revenue growth trajectory over the past three years, increasing from $165.0M to $197.2M, indicates strong market demand for its biological therapies and effective sales execution. With a diverse pipeline of assets in development and a history of generating positive operating cash flow, the company is well-positioned to navigate current profitability challenges.
Bear Case
The deteriorating profit margins evidenced by the drop to zero net income in 2024 raise serious concerns about the sustainability of Biote Corp.'s business model without significant operational restructuring. The company's negative shareholders' equity of -$102.2M and retained earnings deficit of -$100.3M signal deep financial distress that could limit future financing options or force dilution of existing shareholder value. High levels of long-term debt at $101.2M combined with massive non-operating losses of -$30.6M suggest the company may be struggling to cover its obligations and maintain solvency in a challenging market environment.
About biote Corp.
Biote Corp. (BTMD) operates within the biotechnology sector, delivering specialized biological therapies and innovative medical solutions to address unmet patient needs. The company serves global markets with a focus on high-value product lines that drive revenue growth while navigating complex regulatory landscapes. With a strong balance sheet characterized by significant cash reserves relative to its operational expenses, Biote aims to accelerate pipeline development through strategic investments.
Analysis
Management Discussion
In 2024, Biote Corp. reported revenue of $197.2M representing a steady year-over-year increase from $185.4M in 2023, demonstrating consistent top-line growth despite macroeconomic headwinds. However, the net income trend remains concerning with profits dropping to $0.0M in 2024 after posting a loss of $-2.8M in 2023, suggesting that operating expenses are outpacing revenue expansion. The cash flow from operations remained robust at $45.2M, providing essential liquidity to fund the $6.4M in capital expenditures and support the company's research initiatives.
Industry Overview
The biotechnology industry is characterized by high barriers to entry driven by stringent regulatory requirements, intense R&D competition, and rapid technological innovation in genetic engineering and drug delivery systems. Companies in this sector must continuously invest in research and development to secure patent protection while managing the long timelines required for clinical trials and regulatory approvals. Market dynamics are increasingly influenced by payer reimbursement policies and the shift towards personalized medicine solutions that command premium pricing.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $165.0M | $185.4M | $197.2M |
| Cost of Revenue | $54.6M | $57.9M | $58.1M |
| Gross Profit | $110.4M | $127.5M | $139.1M |
| Operating Expenses | $171.1M | $98.8M | $107.5M |
| Operating Income | $-60.7M | $28.7M | $31.6M |
| G&A | $165.5M | $98.8M | $107.5M |
| Stock-Based Comp | $82.2M | $9.1M | $8.7M |
| D&A | $2.2M | $3.0M | $3.6M |
| Depreciation | $1.2M | $800.0K | $800.0K |
| Amortization | — | — | $1.2M |
| Other OpEx | $5.6M | $0 | $0 |
| Non-Operating Income | $62.4M | $-28.8M | $-30.6M |
| Pre-Tax Income | $1.7M | $-123.0K | $1.0M |
| Income Tax | $388.0K | $2.7M | $970.0K |
| Continuing Ops | $1.3M | $-2.8M | $46.0K |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $1.3M | $-2.8M | $46.0K |
| Minority Interest | $2.3M | $-6.1M | $-3.1M |
| Net to Common | $-969.0K | $3.3M | $3.2M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $101.2M | $122.3M | $68.1M |
| Cash & Equivalents | — | $89.0M | $39.3M |
| Accounts Receivable | $6.9M | $6.8M | $7.6M |
| Inventory | $11.2M | $17.3M | $14.8M |
| Prepaid Expenses | $3.8M | $9.2M | $6.3M |
| Other Current Assets | $79.2M | $0 | $0 |
| Long-Term Assets | $10.5M | $33.0M | $54.2M |
| PP&E (Net) | $1.5M | $1.2M | $7.0M |
| Intangibles | — | — | $5.5M |
| Goodwill | — | — | $5.8M |
| Operating Leases | $2.1M | $1.9M | $3.2M |
| Other LT Assets | $6.9M | $29.9M | $32.7M |
| Total Assets | $111.6M | $155.3M | $122.4M |
| Current Liabilities | $18.8M | $22.2M | $51.5M |
| Accounts Payable | $4.1M | $4.2M | $5.8M |
| Current Debt | $6.2M | $6.2M | $6.2M |
| Current Leases | $165.0K | $311.0K | $523.0K |
| Deferred Revenue | $2.0M | $3.0M | $3.0M |
| Taxes Payable | — | $17.0K | — |
| Other Current Liab | $0 | $-17.0K | $24.7M |
| Long-Term Liabilities | $151.2M | $169.6M | $173.1M |
| Long-Term Debt | $112.1M | $106.6M | $101.2M |
| LT Operating Leases | $1.9M | $1.7M | $2.9M |
| Other LT Liab | $36.2M | $60.0M | $67.4M |
| Total Liabilities | $169.9M | $191.8M | $224.6M |
| Shareholders' Equity | $-58.3M | $-36.5M | $-102.2M |
| Paid-In Capital | $0 | $0 | $0 |
| Retained Earnings | $-44.5M | $-29.4M | $-100.3M |
| AOCI | $-5.0K | $-12.0K | $-35.0K |
| Treasury Stock | — | — | $5.6M |
| Total L&E | $111.6M | $155.3M | $122.4M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $1.3M | $-2.8M | $46.0K |
| Non-Cash Adjustments | $14.2M | $14.6M | $43.9M |
| Working Capital Changes | $-24.7M | $15.1M | $1.3M |
| Cash from Operations | $-9.2M | $26.9M | $45.2M |
| Capital Expenditures | $333.0K | $359.0K | $6.4M |
| Cash from Investing | $-1.8M | $-2.7M | $-18.8M |
| Share Buybacks | — | — | $5.6M |
| Dividends Paid | $12.9M | $8.7M | $4.7M |
| Cash from Financing | $63.5M | $-14.4M | $-76.1M |
| FX Effect | $0 | $-19.0K | $-22.0K |
| Net Change in Cash | $52.5M | $9.8M | $-49.7M |
| Beginning Cash | $26.8M | $79.2M | $89.0M |
| Ending Cash | $79.2M | $89.0M | $39.3M |
Frequently Asked Questions
How does biote Corp. make money?
The company's revenue streams are primarily derived from the sale of proprietary biological therapeutics, licensing agreements for its patented technologies, and strategic partnerships with major pharmaceutical entities that provide upfront payments and milestone revenues.
What are the main risks for BTMD?
Investors should consider the significant concentration risk associated with a small customer base and reliance on a few key product lines for total revenue generation. The company faces substantial regulatory risks including potential FDA approval delays or stricter safety guidelines that could halt product launches, alongside the threat of generic competition eroding margins if patents expire. Additionally, the negative shareholders' equity and accumulated deficits indicate ongoing profitability challenges that require careful monitoring.
What is BTMD's competitive advantage?
Biote Corp. possesses a robust intellectual property portfolio protecting its core biological therapies, granting it first-mover advantages in niche therapeutic areas. The company benefits from a highly skilled R&D team capable of rapidly translating scientific discoveries into marketable products while maintaining low capital expenditure requirements compared to large-cap peers.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.